AstraZeneca said today it had agreed to buy Arrow Therapeutics, a privately-owned British biotechnology firm that specialises in anti-viral treatments, for $150 million cash.
AstraZeneca said it expected the acquisition, the latest in a string of deals aimed at boosting its depleted pipeline of new medicines, to close early this year.
AZ signed two deals on Wednesday worth up to $800 million to bring new respiratory and obesity drugs into its pipeline, is due to report 2006 earnings later today.
Reuters
No comments:
Post a Comment